Nigopan Gopalasingam

Nigopan Gopalasingam

Auto-generated profile, based on publicly available information

Nigopan Gopalasingam

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in Circulation
Verified
Journal Article
Open access
PDF file
KHKristoffer Berg Hansen
Kristoffer Berg Hansen
NGNigopan Gopalasingam
Nigopan Gopalasingam
KCKristian Hylleberg Christensen
Kristian Hylleberg Christensen
BLBertil T. Ladefoged
Bertil T. Ladefoged
MAMads Jønsson Andersen
Mads Jønsson Andersen
HWHenrik Wiggers
Henrik Wiggers
BACKGROUND: Heart failure triggers a shift in myocardial metabolic substrate utilization, favoring the ketone body 3-hydroxybutyrate as energy source. We hypothesized that 14-day treatment with ketone ester (KE) would improve resting and exercise hemodynamics and exercise capacity in patients with heart failure with reduced ejection fraction. METHODS: In a randomized, double-blind cross-over study, nondiabetic patients with heart failure with reduced ejection fraction received 14-day KE and 14-day isocaloric non-KE comparator regimens of 4 daily doses separated by a 14-day washout period. After each treatment period, participants underwent right heart catheterization, echocardiography, and blood sampling at plasma trough levels and after dosing. Participants underwent an exercise hemodynamic assessment after a second dosing. The primary end point was resting cardiac output (CO). Secondary end points included resting and exercise pulmonary capillary wedge pressure and peak exercise CO and metabolic equivalents. RESULTS: We included 24 patients with heart failure with reduced ejection fraction (17 men; 65±9 years of age; all White). Resting CO at trough levels was higher after KE compared with isocaloric comparator (5.2±1.1 L/min versus 5.0±1.1 L/min; difference, 0.3 L/min [95% CI, 0.1–0.5), and pulmonary capillary wedge pressure was lower (8±3 mm Hg versus 11±3 mm Hg; difference, −2 mm Hg [95% CI, −4 to −1]). These changes were amplified after KE dosing. Across all exercise intensities, KE treatment was associated with lower mean exercise pulmonary capillary wedge pressure (−3 mm Hg [95% CI, −5 to −1] ) and higher mean CO (0.5 L/min [95% CI, 0.1–0.8]), significantly different at low to moderate steady-state exercise but not at peak. Metabolic equivalents remained similar between treatments. In exploratory analyses, KE treatment was associated with 18% lower NT-proBNP (N-terminal pro-B-type natriuretic peptide; difference, −98 ng/L [95% CI, −185 to −23]), higher left ventricular ejection fraction (37±5 versus 34±5%; P =0.01), and lower left atrial and ventricular volumes. CONCLUSIONS: KE treatment for 14 days was associated with higher CO at rest and lower filling pressures, cardiac volumes, and NT-proBNP levels compared with isocaloric comparator. These changes persisted during exercise and were achieved on top of optimal medical therapy. Sustained modulation of circulating ketone bodies is a potential treatment principle in patients with heart failure with reduced ejection fraction. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05161650.

12 November 2024 in Circulation
Verified
Journal Article
Closed access
NGNigopan Gopalasingam
Nigopan Gopalasingam
KHKristoffer Berg Hansen
Kristoffer Berg Hansen
KCKristian Hylleberg Christensen
Kristian Hylleberg Christensen
BLBertil T. Ladefoged
Bertil T. Ladefoged
SPSteen Hvitfeldt Poulsen
Steen Hvitfeldt Poulsen
HWHenrik Wiggers
Henrik Wiggers
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major cause of morbidity and mortality in patients with type 2 diabetes (T2D). Acute increases in circulating levels of ketone body 3-hydroxybutyrate have beneficial acute hemodynamic effects in patients without T2D with chronic heart failure with reduced ejection fraction. However, the cardiovascular effects of prolonged oral ketone ester (KE) treatment in patients with T2D and HFpEF remain unknown. METHODS: A total of 24 patients with T2D and HFpEF completed a 6-week randomized, double-blind crossover study. All patients received 2 weeks of KE treatment (25 g D-ß-hydroxybutyrate-(R)-1,3-butanediol × 4 daily) and isocaloric and isovolumic placebo, separated by a 2-week washout period. At the end of each treatment period, patients underwent right heart catheterization, echocardiography, and blood samples at trough levels of intervention, and then during a 4-hour resting period after a single dose. A subsequent second dose was administered, followed by an exercise test. The primary end point was cardiac output during the 4-hour rest period. RESULTS: During the 4-hour resting period, circulating 3-hydroxybutyrate levels were 10-fold higher after KE treatment (1010±56 µmol/L; P <0.001) compared with placebo (91±55 µmol/L). Compared with placebo, KE treatment increased cardiac output by 0.2 L/min (95% CI, 0.1 to 0.3) during the 4-hour period and decreased pulmonary capillary wedge pressure at rest by 1 mm Hg (95% CI, –2 to 0) and at peak exercise by 5 mm Hg (95% CI, –9 to –1). KE treatment decreased the pressure-flow relationship (∆ pulmonary capillary wedge pressure/∆ cardiac output) significantly during exercise ( P <0.001) and increased stroke volume by 10 mL (95% CI, 0 to 20) at peak exercise. KE right-shifted the left ventricular end-diastolic pressure-volume relationship, suggestive of reduced left ventricular stiffness and improved compliance. Favorable hemodynamic responses of KE treatment were also observed in patients treated with sodium-glucose transporter-2 inhibitors and glucagon-like peptide-1 analogs. CONCLUSIONS: In patients with T2D and HFpEF, a 2-week oral KE treatment increased cardiac output and reduced cardiac filling pressures and ventricular stiffness. At peak exercise, KE treatment markedly decreased pulmonary capillary wedge pressure and improved pressure-flow relationship. Modulation of circulating ketone levels is a potential new treatment modality for patients with T2D and HFpEF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05236335.

16 May 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
RNRoni Nielsen
Roni Nielsen
KCKristian Hylleberg Christensen
Kristian Hylleberg Christensen
NGNigopan Gopalasingam
Nigopan Gopalasingam
KHKristoffer Berg Hansen
Kristoffer Berg Hansen
JSJacob Seefeldt
Jacob Seefeldt
SMSøren Mellemkjær
Søren Mellemkjær
Background: Pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) are debilitating diseases with a high mortality. Despite emerging treatments, pulmonary vascular resistance frequently remains elevated. However, the ketone body 3‐hydroxybutyrate (3‐OHB) may reduce pulmonary vascular resistance in these patients. Hence, the aim was to assess the hemodynamic effects of 3‐OHB in patients with PAH or CTEPH. Methods and Results: We enrolled patients with PAH (n=10) or CTEPH (n=10) and residual pulmonary hypertension. They received 3‐OHB infusion and placebo (saline) for 2 hours in a randomized crossover study. Invasive hemodynamic and echocardiography measurements were performed. Furthermore, we investigated the effects of 3‐OHB on the right ventricle of isolated hearts and isolated pulmonary arteries from Sprague–Dawley rats. Ketone body infusion increased circulating 3‐OHB levels from 0.5±0.5 to 3.4±0.7 mmol/L ( P <0.001). Cardiac output improved by 1.2±0.1 L/min (27±3%, P <0.001), and right ventricular annular systolic velocity increased by 1.4±0.4 cm/s (13±4%, P =0.002). Pulmonary vascular resistance decreased by 1.3±0.3 Wood units (18%±4%, P <0.001) with no significant difference in response between patients with PAH and CTEPH. In the rat studies, 3‐OHB administration was associated with decreased pulmonary arterial tension compared with saline administration (maximal relative tension difference: 12±2%, P <0.001) and had no effect on right ventricular systolic pressures ( P =0.63), whereas pressures rose at a slower pace (dP/dtmax, P =0.02). Conclusions: In patients with PAH or CTEPH, ketone body infusion improves cardiac output and decreases pulmonary vascular resistance. Experimental rat studies support that ketone bodies relax pulmonary arteries. Long‐term studies are warranted to assess the clinical role of hyperketonemia. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04615754.

9 May 2017 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Closed access
PDF file
NGN. Gopalasingam
N. Gopalasingam
DOD. S. Obad
D. S. Obad
BKB. S. Kristensen
B. S. Kristensen
PLP. Lundgaard
P. Lundgaard
MVM. Veien
M. Veien
PJP. Juhl‐Olsen
P. Juhl‐Olsen

16 March 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
OHOskar Kjærgaard Hørsdal
Oskar Kjærgaard Hørsdal
NMNiels Moeslund
Niels Moeslund
KBKristoffer Berg-Hansen
Kristoffer Berg-Hansen
RNRoni Nielsen
Roni Nielsen
NMNiels Møller
Niels Møller
NGNigopan Gopalasingam
Nigopan Gopalasingam
Background: Lactate is traditionally recognized as a by-product of anaerobic metabolism. However, lactate is a preferred oxidative substrate for stressed myocardium. Exogenous lactate infusion increases cardiac output (CO). The exact mechanism underlying this mechanism has yet to be elucidated. The aim of this study was to investigate the cardiovascular mechanisms underlying the acute haemodynamic effects of exogenous lactate infusion in an experimental model of human-sized pigs. Methods: In this randomised, blinded crossover study in eight 60-kg-pigs, the pigs received infusions with one molar sodium lactate and a control infusion of tonicity matched hypertonic saline in random order. We measured CO and pulmonary pressures using a pulmonary artery catheter. A pressure–volume admittance catheter in the left ventricle was used to measure contractility, afterload, preload and work-related parameters. Results: Lactate infusion increased circulating lactate levels by 9.9 mmol/L (95% confidence interval (CI) 9.1 to 11.0) and CO by 2.0 L/min (95% CI 1.2 to 2.7). Afterload decreased as arterial elastance fell by -1.0 mmHg/ml (95% CI -2.0 to -0.1) and systemic vascular resistance decreased by -548 dynes/s/cm5 (95% CI -261 to -835). Mixed venous saturation increased by 11 percentage points (95% CI 6 to 16), whereas ejection fraction increased by 16.0 percentage points (95% CI 1.1 to 32.0) and heart rate by 21 bpm (95% CI 8 to 33). No significant changes in contractility nor preload were observed. Conclusion: Lactate infusion increased cardiac output by increasing heart rate and lowering afterload. No differences were observed in left ventricular contractility or preload. Lactate holds potential as a treatment in situations with lowered CO and should be investigated in future clinical studies. Graphical

20 June 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
NGNigopan Gopalasingam
Nigopan Gopalasingam
KCKristian Hylleberg Christensen
Kristian Hylleberg Christensen
KHKristoffer Berg Hansen
Kristoffer Berg Hansen
RNRoni Nielsen
Roni Nielsen
MJMogens Johannsen
Mogens Johannsen
HWHenrik Wiggers
Henrik Wiggers
Background: The ketone body 3‐hydroxybutyrate (3‐OHB) increases cardiac output (CO) in patients with heart failure through unknown mechanisms. 3‐OHB activates the hydroxycarboxylic acid receptor 2 (HCA 2 ), which increases prostaglandins and suppresses circulating free fatty acids. We investigated whether the cardiovascular effects of 3‐OHB involved HCA 2 activation and if the potent HCA 2 ‐stimulator niacin may increase CO. Methods and Results: Twelve patients with heart failure with reduced ejection fraction were included in a randomized crossover study and examined by right heart catheterization, echocardiography, and blood sampling on 2 separate days. On study day 1, patients received aspirin to block the HCA 2 downstream cyclooxygenase enzyme, followed by 3‐OHB and placebo infusions in random order. We compared the results with those of a previous study in which patients received no aspirin. On study day 2, patients received niacin and placebo. The primary end point was CO. 3‐OHB increased CO (2.3 L/min, P <0.01), stroke volume (19 mL, P <0.01), heart rate (10 bpm, P <0.01), and mixed venous saturation (5%, P <0.01) with preceding aspirin. 3‐OHB did not change prostaglandin levels, neither in the ketone/placebo group receiving aspirin nor the previous study cohort. Aspirin did not block 3‐OHB‐induced changes in CO ( P =0.43). 3‐OHB decreased free fatty acids by 58% ( P =0.01). Niacin increased prostaglandin D 2 levels by 330% ( P <0.02) and reduced free fatty acids by 75% ( P <0.01) but did not affect CO. Conclusions: The acute increase in CO during 3‐OHB infusion was not modified by aspirin, and niacin had no hemodynamic effects. These findings show that HCA 2 receptor‐mediated effects were not involved in the hemodynamic response to 3‐OHB. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04703361.